Bio-Technology General Corp. Announces Oxandrolone Presentations At Endo 2002 Meeting.

Business Editors

ISELIN, N.J.--(BUSINESS WIRE)--June 17, 2002

Bio-Technology General Corp. (NASDAQ:BTGC) announces the following presentations on its product oxandrolone (Oxandrin(R)) at ENDO 2002, the 84th Annual Meeting of the National Endocrine Society, in San Francisco, June 19-22, 2002. Founded in 1916, The Endocrine Society is the world's oldest, largest, and most active organization devoted to research on hormones and the clinical practice of endocrinology, with membership of over 10,000 in more than 80 countries.

The primary presentation, entitled "Muscle Strength and Power Changes with 12 Weeks of Oral Androgen Therapy in Older Adult Men" is an investigator-initiated placebo-controlled study of oxandrolone in age-related sarcopenia, or muscle wasting, in men aged 60 to 87 years. The presentation was one of approximately 125 selected by The Society from over 2,500 abstracts submitted to ENDO 2002 to be included in the Research Summaries Book (RSB). The RSB is a resource for the media during ENDO and throughout the rest of the year. This oral presentation will be part of the Clinical Science Session on Aging on Saturday, June 22 at 1:45 pm in Location 103.

Two additional abstracts from the sarcopenia study were chosen for poster presentation the day prior to the oral presentation. These companion presentations are entitled "Body Composition Changes with 12 Weeks of Oral Androgen Therapy in Older Adult Men" and "Alterations in Blood Lipid Profiles and Body Fat with 12 Weeks of Oral Androgen Therapy in Older Adult Men" and will be available for viewing from 11 am at the Exhibit Hall with discussion with investigators from the University of Southern California's Departments of Internal Medicine and Biokinesiology.

Oxandrolone is a synthetic derivative of testosterone indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma, and in some patients who without definite pathophysiologic reasons fail to gain or to maintain normal weight, to offset the protein catabolism associated with prolonged administration of corticosteroids, and for the relief of the bone pain frequently accompanying osteoporosis.

Bio-Technology General Corp., a leading biopharmaceutical company, develops, manufactures and markets genetically engineered and other products for human health care. BTG's products are marketed worldwide. Products sold in the United States are Oxandrin(R) (oxandrolone, USP), marketed by BTG and by the Ross Products Division of Abbott Laboratories under a co-marketing agreement, Delatestryl(R) (testosterone enanthate), marketed by BTG, Mircette(R) (oral contraceptive), marketed by Organon, Inc., and BioLon(TM) (sodium hyaluronate), marketed by Akorn, Inc. Products sold internationally are Bio-Tropin(TM) (recombinant human growth hormone), BioLon(TM) (sodium hyaluronate), Bio-Hep-B(TM) (hepatitis B vaccine), Arthrease(TM) (sodium hyaluronate for osteoarthritis), and Silkis(R) (vitamin D derivative). BTG's news releases and other information are available on the Company's website at www.btgc.com.

Arthrease is a trademark of DePuy Orthopaedics, Inc., Mircette is a registered trademark of Organon, Inc., Silkis is a registered trademark of Galderma.

Statements in this news release concerning the Company's business outlook or future economic performance, anticipated profitability, revenues, expenses or other financial items; and statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements" as that term is defined under the Federal Securities Laws. Forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to, changes and delays in product development plans and schedules, customer acceptance of new products, changes in pricing or other actions by competitors, patents owned by the Company and its competitors, and general economic conditions, as well as other risks detailed in the Company's filings with the Securities and Exchange Commission.